RecruitingNot Applicable

Precision Medicine for L/GCMN and Melanoma 2

Spain100 participantsStarted 2025-01-01

Plain-language summary

The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Be over 18 years old * Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC) Exclusion Criteria: * Not signing the informed consent form * Present other cancers or chronic diseases (such as diabetes, asthma, etc.), which may affect the volatile organic compound profiles

What they're measuring

Early identification of metastases

Timeframe: 24 months

Trial details

NCT IDNCT06605443

SponsorFundacion Clinic per a la Recerca Biomédica

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-09-01

Contact for this trial

Susana Puig Sardà, PhD, MD

+34932275400 spuig@clinic.cat

View on ClinicalTrials.gov More Melanoma (Skin Cancer) trials